Drugs / sincalide
sincalide
also known as
Cck c-terminal octapeptide · CCK-8 · Cck-8s · Cholecystokinin c-terminal octapeptide · Cholecystokinin Octapeptide · Kinevac · Sincalida · SQ 19844
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | KINEVAC | — | 1986-08-25 | fda.gov ↗ |
| Approved | US (FDA) | KINEVAC | — | 1976-07-21 | fda.gov ↗ |
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00706381 | Jun 2008 → Aug 2012 | — | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | Mixed |
| Phase not applicable1 trial | ||||||
| — | NCT00004414 | Sep 1997 → Jun 2002 | cholestasis | University of Michigan | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT04567667 Background | Oct 2020 → Apr 2021 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| — | NCT00685477 Comparator | May 2008 → May 2009 | — | Temple University | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sincalide | “This multicenter trial establishes a GBEF lower limit of normal of 38% (first percentile) for a 60-min infusion of 0.02 microg of sincalide per kilogram, quantified at 60 min.” PMID 20080900 ↗ Jan 2010 |
| Known as | Cck c-terminal octapeptide | ChEMBL registry synonym — accepted as the source's own label CHEMBL1121 ↗ |
| Known as | CCK-8 | “Dose Response of Intravenous Sincalide (CCK-8) for Gallbladder Emptying” NCT00685477 ↗ |
| Known as | Cck-8s | ChEMBL registry synonym — accepted as the source's own label CHEMBL1121 ↗ |
| Known as | Cholecystokinin c-terminal octapeptide | ChEMBL registry synonym — accepted as the source's own label CHEMBL1121 ↗ |
| Known as | Cholecystokinin Octapeptide | “Sincalide (Cholecystokinin Octapeptide) Versus Placebo” NCT00004414 ↗ |
| Known as | Kinevac | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04567667 ↗ |
| Known as | Sincalida | ChEMBL registry synonym — accepted as the source's own label CHEMBL1121 ↗ |
| Known as | SQ 19844 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1121 ↗ |
| Action | Activate | “Cholecystokinin A receptor agonist” CHEMBL1121 ↗ |
| Modality | Peptide | “the C-terminal octapeptide fragment of cholecystokinin” NCT00706381 ↗ |
| Route | Intravenous | “sincalide IV over 10 to 15 minutes” NCT00004414 ↗ |
| Target | CCKAR | “Cholecystokinin A receptor agonist” CHEMBL1121 ↗ |